Bristol‑Myers Squibb
The rounds this investor is named on, who it invests beside, and where it shows up.
The rounds this investor is named on, who it invests beside, and where it shows up.
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Pathos AI Pathos integrates AI technology, biological modeling, and the largest collection of oncology patient data to make clinical trials smarter and more precise. | Series E Verified against 3 of 40 sources | $237M | 2026-10-23 | [ LEAD ] |
Beeline Medicines A startup focused on precision therapies for autoimmune and inflammatory diseases | Series A ext. |
| $126M |
| 2026-06-30 |
| [ PART ] |
Link Cell Therapies An oncology cell therapy company utilizing its proprietary logic-gating technology to develop next-generation CAR-T therapeutics for solid tumors and hematologic malignancies | Series A Verified against 1 of 4 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $60M | 2025-12-15 | [ PART ] |
GlycoEra Biologics aimed at precision immunology, targeting and degrading specific proteins associated with autoimmune diseases for improved patient outcomes. | Series B Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $130M | 2025-05-27 | [ PART ] |
Cellares Cellares specializes in advanced manufacturing technologies for cell therapy, targeting biopharmaceutical companies and healthcare providers. | Series C Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $255M | 2023-08-23 | [ PART ] |
BigHat Biosciences A clinical-stage, AI-driven protein therapeutics platform company | Series B Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $75M | 2022-07-20 | [ PART ] |